Rallybio Corp. (RALLY) has agreed to acquire Candid Therapeutics (CAND) in a transaction valued at approximately $680 million, combining two biotechnology firms focused on rare disease treatments. The all-stock deal underscores growing consolidation in the specialty pharmaceutical sector.
- Deal value: ~$680 million in all-stock transaction
- Rallybio (RALLY) to issue 0.35 shares for each CAND share
- 32% premium to Candid Therapeutics’ 30-day VWAP
- Candid’s Phase 2 candidate CT-104 for rare mitochondrial disease
- Expected closing: Q3 2026, subject to regulatory and shareholder approval
- Post-announcement stock movements: RALLY +8.7%, CAND +24.3%
Rallybio has entered into a definitive agreement to acquire Candid Therapeutics in an all-stock transaction valued at roughly $680 million, based on the closing price of Rallybio’s shares on March 1, 2026. The deal, which requires regulatory approval and customary closing conditions, positions Rallybio to expand its pipeline in rare and ultra-rare genetic disorders, particularly those involving metabolic and neurological pathways. Candid Therapeutics brings forward a lead candidate, CT-104, currently in Phase 2 clinical trials for a rare mitochondrial disease. The company also holds preclinical assets in neurodegenerative conditions, which are expected to complement Rallybio’s existing portfolio, including its approved therapy for a lysosomal storage disorder. The transaction is structured to allow Candid shareholders to receive 0.35 shares of Rallybio for each CAND share held, representing a 32% premium to the 30-day volume-weighted average price prior to announcement. The acquisition is expected to enhance Rallybio’s commercial and development capabilities, with synergies anticipated in research, regulatory strategy, and patient outreach. Analysts note that the deal reflects a broader trend of biotech consolidation as companies seek to de-risk development pipelines and strengthen market positioning in niche therapeutic areas. The combined entity will have a focus on gene and protein therapies targeting underserved patient populations. Rallybio’s shares rose 8.7% in after-hours trading following the announcement, while Candid Therapeutics’ stock gained 24.3%. The transaction is expected to close in the third quarter of 2026, pending approvals from the relevant regulatory authorities and shareholder votes.